"Leucovorin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
| Descriptor ID |
D002955
|
| MeSH Number(s) |
D03.633.100.733.631.400.800.350.450 D08.211.840.300.500
|
| Concept/Terms |
Leucovorin- Leucovorin
- Folinic Acid-SF
- Folinic Acid SF
- Leukovorin
- Leukovorum
- Folinic Acid
- Acid, Folinic
Citrovorum Factor- Citrovorum Factor
- Factor, Citrovorum
- Calcium Leucovorin
- Leucovorin, Calcium
- Calcium Folinate
- Folinate, Calcium
N(5)-Formyltetrahydrofolate- N(5)-Formyltetrahydrofolate
- 5-Formyltetrahydropteroylglutamate
- 5 Formyltetrahydropteroylglutamate
- 5-Formyltetrahydrofolate
- 5 Formyltetrahydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Leucovorin".
Below are MeSH descriptors whose meaning is more specific than "Leucovorin".
This graph shows the total number of publications written about "Leucovorin" by people in this website by year, and whether "Leucovorin" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 4 | 8 |
| 1996 | 0 | 6 | 6 |
| 1997 | 2 | 3 | 5 |
| 1998 | 0 | 3 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 1 | 2 | 3 |
| 2002 | 1 | 2 | 3 |
| 2003 | 0 | 7 | 7 |
| 2004 | 0 | 4 | 4 |
| 2005 | 1 | 5 | 6 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 9 | 9 |
| 2009 | 2 | 3 | 5 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 8 | 8 |
| 2012 | 1 | 4 | 5 |
| 2013 | 1 | 10 | 11 |
| 2014 | 1 | 11 | 12 |
| 2015 | 0 | 11 | 11 |
| 2016 | 0 | 10 | 10 |
| 2017 | 0 | 15 | 15 |
| 2018 | 0 | 22 | 22 |
| 2019 | 0 | 12 | 12 |
| 2020 | 1 | 14 | 15 |
| 2021 | 1 | 11 | 12 |
| 2022 | 0 | 18 | 18 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 1 | 5 |
| 2025 | 1 | 2 | 3 |
Below are the most recent publications written about "Leucovorin" by people in Profiles.
-
Microglia-Mediated Synaptic Dysfunction Contributes to Chemotherapy-Related Cognitive Impairment. J Neurochem. 2025 Mar; 169(3):e70024.
-
Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. Cancer. 2025 Feb 15; 131(4):e35759.
-
Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial. JNCI Cancer Spectr. 2025 Jan 03; 9(1).
-
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. J Clin Oncol. 2025 Mar; 43(7):840-851.
-
First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease. Anticancer Res. 2024 Sep; 44(9):3885-3889.
-
Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Ann Surg Oncol. 2024 Sep; 31(9):6147-6156.
-
Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clin Cancer Res. 2024 May 15; 30(10):2039-2047.
-
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial. Cancer Res Commun. 2024 01 04; 4(1):28-37.
-
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023 07 20; 41(21):3724-3734.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.